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NeuroinﬂammationThe number of patients with Alzheimer's disease (AD) is increasing worldwide, and available drugs have shown
limited efﬁcacy. Hence, preventive interventions and treatments for presymptomatic AD are currently considered
very important. Obesity rates have also been increasing dramatically and it is an independent risk factor
of AD. Therefore, for the prevention of AD, it is important to elucidate the pathomechanism between obesity
and AD. We generated high calorie diet (HCD)-induced obese tauopathy model mice (PS19), which showed
hyperleptinemia but limited insulin resistance. HCD enhanced tau pathology and glial activation. Conversely,
voluntary exercise with a running wheel normalized the serum leptin concentration without reducing
body weight, and restored the pathological changes induced by HCD. Thus, we speculated that persistent
hyperleptinemia played an important role in accelerating pathological changes in PS19 mice. Leptin primarily
regulates food intake and body weight via leptin receptor b (LepRb). Interestingly, the nuclear staining for
p-STAT3, which was activated by LepRb, was decreased in hippocampal neurons in HCDPS19mice, indicating
leptin resistance. Meanwhile, astroglial activation and the astrocytic expression of a short LepR isoform, LepRa,
were enhanced in the hippocampus of HCD PS19mice. Real-time PCR analysis demonstrated that leptin increased
mRNA levels for pro-inﬂammatory cytokines including IL-1β and TNF-α in primary cultured astrocytes fromwild
type and LepRb-deﬁcient mice. These observations suggest that persistent hyperleptinemia caused by obesity
induces astrocytic activation, astrocytic leptin hypersensitivity with enhanced LepRa expression, and enhanced
inﬂammation, consequently accelerating tau pathology in PS19 mice.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
The rapid increase in the size of the elderly population has resulted
in a dramatic increase in the number of patients with dementia. Of all
diseases causing dementia, Alzheimer's disease (AD) is the most preva-
lent, contributing up to 60–70% of all dementia cases. Current therapies
for AD only provide symptomatic relief, either by temporarily improving
symptoms above baseline or by delaying cognitive decline. Thus, disease-
modifying therapies based on the pathomechanisms of AD are a central
focus of AD drug discovery. Although the pathomechanisms of AD are
still unclear, β-amyloid protein (Aβ) and tau protein are common targets
for disease-modifying therapies. However, recent clinical trials based on
the amyloid hypothesis and aiming to reduce the production of Aβ or, Chiba 260, Japan. Fax: +81 43
).
ect.com).
. This is an open access article underto remove the accumulated Aβ from the brain have failed to demonstrate
signiﬁcant clinical efﬁcacy, although the hope that these therapies will
have some beneﬁcial effects has not been completely abandoned. Addi-
tionally, tau-targeting therapies have also failed to yield results for the
treatment of AD and related tauopathies, although tau pathology is
thought to be more directly related to neurodegeneration and cognitive
decline than Aβ pathology (Yoshiyama et al., 2013). Along with these
clinical observations, disease-modifying therapies have shown limited
efﬁcacy towards improving symptomatic AD patients. Therefore, to
prevent the onset of clinical symptoms of AD, researchers have
turned their attention to the relationship between lifestyle and AD.
Lifestyle-related diseases are potentially preventable, and can be de-
creasedwith adequate changes in diet, physical activity, and environment
without incurring excessive expense. The common feature at the core of
most lifestyle diseases is obesity, rates of which have dramatically
increased. Worldwide, age-standardized prevalence of obesity was esti-
mated to be 9.8% in men and 13.8% in woman in 2008, and the highestthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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2011). Although it is well-known that obesity is an independent risk fac-
tor of AD (Kivipelto et al., 2005; Whitmer et al., 2007; Gustafson et al.,
2009; Li et al., 2010; Profenno et al., 2010), obesity induces other AD
risk factors. It is therefore difﬁcult to clarify the effects obesity itself and
its mechanisms have on AD while excluding other contributing factors
and complications related to obesity (such as diabetes mellitus) in
human research. Thus, it is important to generate appropriate models to
evaluate the pathological relationship between obesity and AD.
High calorie diets (HCD) used in a majority of diet-induced obesity
studies usually contain around 550 cal/100 g, and typically induce glu-
cose metabolism abnormalities and insulin resistance (diabetes
mellitus). To develop an obese tauopathymousemodel with fewer com-
plicating factors induced by obesity, we used a moderately high calorie
diet containing 415 cal/100 g. This allowed us to develop an obese
tauopathy mouse model that showed obvious hyperleptinemia but lim-
ited insulin resistance. Interestingly, both tau pathology and glial activa-
tionwere enhanced in thesemice, and the expression of certain isoforms
of leptin receptor (LepR)was enhanced in astrocytes.Meanwhile, volun-
tary exercise (EX) with a running wheel reduced hyperleptinemia with-
out altering body weight, and also reduced the tau pathology and glial
activation. These ﬁndings suggest that the persistent hyperleptinemia
might be an important factor that enhances tau pathology.
Methods
Animals
The generation of transgenic (Tg) mice carrying the human tau
gene harboring a P301S mutation was previously described by our
group (Yoshiyama et al., 2007). Brieﬂy, a cDNA construct of human
tau isoform T34 (1N4R) harboring the P301S mutation was cloned
into the MoPrP.Xho expression vector containing a mouse prion
(MoPrP) promoter (Borchelt et al., 1996) at the XhoI site. A 15-kb
NotI fragment containing T34 and the MoPrP promoter together with
39 bp of untranslated sequence was used as the transgene to create
tau Tg mice in a B6C3H/F1 background. A stable Tg line (PS19) and
non-Tg offspring were identiﬁed by PCR analysis of tail genomic DNA.
To reduce potential variations in tau pathology, body weight and
metabolism, we used only female mice. Female PS19 mice were exposed
to either HCD [15.3% fat (source: beef tallow; composition: saturated,
41%; monosaturated, 44%; polysaturated, 10%: oleic acid, 40%; palmitic
acid, 24%; stearic acid, 14%; linoleic acid (n-6), 9%; linolenic acid (n-3),
1%), 415 cal/100 g, Quick Fat (Clea Japan Inc., Japan)] or standard rodent
laboratory diet (SD) (4.5 % fat, 330 cal/100 g, Lab Diet 5 L65, Japan SLC,
Inc., Japan) from 1.5 to 10 months of age.
The animals in the HCD group were housed in either a regular cage
or a cage equipped with a running wheel (CL-4579-2. Clea Japan, Inc.,
Japan) (from 1.5 to 10 months of age). The average amount of exercise
was 9.0 ± 2.0 × 103 rounds/day (≈5.6 ± 1.2 km/day, mean ± SD). At
10 months of age, animals were decapitated, and blood (500–700 μl)
was collected from the left ventricle of the heart for analysis. Serum
samples were stored at−80 °C until measurements. Brain specimens
were harvested andhemi-dissected:Onehemispherewasmicrodissected
and the other was postﬁxed in 4% PFA. All tissues used for biochemical
analysis were stored at−80 °C, whereas tissue processed for immuno-
histochemistry was stored at 4 °C. There was no difference in survival
among any of the groups. The ﬁnal numbers of subjects in the SD, HCD,
and HCD+ EX groups for this study were 13, 12, and 10, respectively.
All experiments were approved by the Committee of Animal Care
and Control in Chiba East National Hospital.
Assessment of metabolic changes
Body weight was recorded every 4 weeks throughout the study.
Fasting serum insulin and leptin levels were determined using theenzyme-linked immunosorbent assay (ELISA) kit (Morinaga Institute
of Science, Inc., Japan). Fasting serum total cholesterol level was deter-
mined using a colorimetric assay performed with commercial reagents
(BioVision, Inc., San Francisco, CA, USA). Fasting serum triglyceride level
was determined using Accutrend GCT (Roche Diagnostics, Switzerland).
Intraperitoneal glucose tolerance tests (IGTT) were performed in PS19
mice (SD, n = 12; HCD, n = 13; HCD + EX, n = 6) one week before
sacriﬁce. On the night before the IGTTs, food was removed at 6:00 PM,
and at 9 AM the next day, andmice were given a single-dose intraperito-
neal injection of glucose (2 g/kg body weight) (15 hours fasting). Blood
samples were collected from the tail vein immediately before glucose
administration and again at 15, 30, 60, and 120 min post-gavage. Blood
glucose was assessed using Glutest Ace R (Sanwa Kagaku Kenkyusho
Co., Ltd., Japan) following the manufacturer's instructions. Insulin
tolerance tests (ITTs) were performed in PS19 mice (SD, n = 10;
HCD, n = 12; HCD + EX, n = 6) two weeks before sacriﬁce. The
mice were intraperitoneally injected with insulin (0.75 U/kg diluted
in 0.1 ml of 0.9% NaCl). Blood samples were collected from the tail vein
immediately before the injection of insulin and again at 15, 30, 45, 60,
and 120 min after the insulin injection. Blood glucose was assessed by
using Glutest Ace R.
Tau insolubility and phosphorylation states
Proteins were extracted by solubilizing brain tissue in radio-
immunoprecipitation assay (RIPA) buffer [50 mM Tris, 150 mM NaCl,
0.1% SDS, 0.5% sodium deoxycholate, 1% NP40, 5mM EDTA, and protease
inhibitor cocktail (protease inhibitor cocktail set I (Calbiochem, Merck,
Germany); ﬁnal pH 8.0)], using 1 ml/g. Samples were then centrifuged
at 40,000 g for 40 min at 4 °C. The supernatants were used as RIPA-
soluble samples, while the RIPA-insoluble pellets were extracted using
70% formic acid (FA) to recover highly insoluble protein.
Imaging and statistical analyses
Images were captured with a Nikon Eclipse 80i microscope and a
Nikon DXM 1200C digital camera, and analyzed using ImageJ software
(National Institutes of Health, Bethesda, MD). The results were expressed
as themean±SE. Statistically signiﬁcant differenceswere determined by
analysis of variance using SPSS statistical software (SPSS, Chicago, IL,
USA). Statistical signiﬁcance was set at P b 0.05.
Western blot analysis
Protein concentrations of RIPA-extracted samples were determined
using a BCA protein assay kit (Pierce, Rockford, IL), and proteins were
resolved by SDS-PAGE, followed by western blotting. Signals were
detected by enhanced chemiluminescence (GE Healthcare, WI, USA)
according to the manufacturer's instructions. The antibodies and corre-
sponding dilutions used are listed in Table 1.
Primary cortical astrocyte cultures
Enriched cultures of astrocytes were generated using the method
developed by McCarthy and de Vellis (1980). First, mixed glia cultures
were generated from1- to 2-day-oldmice.Mouse brainswere aseptically
removed and placed in sterile culture dishes containing Hank's balanced
salt solution. The meninges and blood vessels were removed by dissec-
tion, and the cerebral cortices (including the hippocampus)were isolated
from the brain. The cerebral cortices were mechanically dissociated and
suspended in Dulbecco's Modiﬁed Eagle Medium (DMEM) supplement-
ed with 10% fetal bovine serum, 7.5 mM glucose, 4 mM L-glutamine,
1000 U/ml penicillin, and 1 ng/ml streptomycin. Next, cells were centri-
fuged at 2000 rpm for 5 min, resuspended in 10% DMEM, and placed in
75-cm2 ﬂask. Cultures were maintained in 10% DMEM at 37 °C in an at-
mosphere of 5% CO2. After oneweek, cells weremechanically dissociated
Table 1
Primary antibodies used in this study.
Antibody Immunogen Host Dilution for IHC Dilution
for WB
Source
17026 Total tau Rabbit ×1000 Ishihara et al., 1999
T181 Anti-phospho-Tau (pThr181) Rabbit ×1000 Sigma (Sigma-Aldrich, MO)
Syntaxin Synaptic vesicle containing fractions of immunoprecipitated
human brain homogenate
Mouse ×500 Santa Cruz Biotechnology (Santa Cruz, CA)
Iba1 C terminus of Iba1 Rabbit ×1000 Wako (Osaka, Japan)
SAPK/JNK Human JNK2 Rabbit ×1000 Cell Signaling (Beberly, MA)
p-SAPK/JNK Phosphopeptide surrounding Thr183/Tyr185 of
human SAPK/JNK
Rabbit ×1000 Cell Signaling (Beberly, MA)
GSK-3β aa 345–420 of human GSK-3β Rabbit ×500 Santa Cruz Biotechnology (Santa Cruz, CA)
p-GSK-3β aa containing phosphorylated ser9 of human GSK-3β Goat ×500 Santa Cruz Biotechnology (Santa Cruz, CA)
CDK5 aa 1–291 of human cdk5 Mouse ×500 Santa Cruz Biotechnology (Santa Cruz, CA)
p-CDK5 aa containing phosphorylated Ser159 of human cdk5 Goat ×500 Santa Cruz Biotechnology (Santa Cruz, CA)
p38 MAPK aa corresponding to residues near the carboxy terminus of human p38 protein. Rabbit ×1000 Cell Signaling (Beberly, MA)
p-p38MAPK Phosphopeptides surrounding Thr180/Tyr182 of human p38 Rabbit ×1000 Cell Signaling (Beberly, MA)
p-p38MAPK Phosphopeptides surrounding Thr180/Tyr182 of human p38 Mouse ×1000 Cell Signaling (Beberly, MA)
ERK1/2 aa corresponding to residues near the C-terminus of rat p44 MAP kinase Rabbit ×1000 Cell Signaling (Beberly, MA)
p-ERK1/2 aa corresponding to residues near the C-terminus of rat p44 MAP kinase Rabbit ×1000 Cell Signaling (Beberly, MA)
α-tubulin aa 426–430 of alpha-tubulin Mouse ×1000 Sigma (Sigma-Aldrich, MO)
M18 aa 877–894 of leptin receptor, highest for leptin receptor a,
less for leptin receptor c and d
Goat ×100 Santa Cruz Biotechnology (Santa Cruz, CA)
K20 N-terminal of leptin receptor (all isoforms) Chicken ×100 Santa Cruz Biotechnology (Santa Cruz, CA)
CH14014 Leptin receptor b Chicken ×100 Neuromics Antibody (Neuromics, MN)
pAKT p-Akt1/2/3 (Ser 473) Rabbit ×500 Santa Cruz Biotechnology (Santa Cruz, CA)
pSTAT3 phosphorylated STAT3 at Tyr705 Rabbit ×100 Cell Signaling (Beberly, MA)
AMPK N-terminal sequence of human AMPKα Rabbit ×1000 Cell Signaling (Beberly, MA)
pAMPK Phospho-AMPKα (Thr172) Rabbit ×1000 Cell Signaling (Beberly, MA)
GFAP Recombinant GFAP Chicken ×1000 Neuromics Antibody (Neuromics, MN)
IHC, immunohistochemistory; WB, western blotting.
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harvested by trypsinization, plated in 3.5 cm dishes, and maintained in
10% DMEM for one day to reach almost 80% conﬂuency. One day prior
to experiments, cultures were switched to full DMEM. For the leptin
load experiment, astrocytes were incubated in 10% DMEM plus varying
concentrations of leptin for one day.RT-PCR analysis of mRNA of leptin receptor subtypes in cultured mouse
astrocytes
Total RNA was extracted using an RNeasy Plus Mini Kit (Qiagen,
Venlo, Netherlands), and ﬁrst-strand cDNA was synthesized using
SuperScript VILO cDNA synthesis kit (Invitrogen, Carlsbad, CA, USA).
The PCR condition for LepRa was as follows: denaturation at 95 °C for
5min, followed by 35 cycles of denaturation at 95 °C for 1min, annealing
at 55 °C for 1 min, and extension at 72 °C for 1 min. PCR conditions for
other LepR isoforms used the same conditions, except for the annealing
temperature (LepRb at 59 °C, LepRc at 54 °C, LepRd at 48 °C and LepRe
at 54 °C). The primer sequences were generated by Hsuchou et al.
(2009).Real-time PCR
ThemRNA levels of IL-1β, CCL2 andTNF-α transcriptswere analyzed
by quantitative real-time PCR using the ABI PRISM® 7900HT sequence
detection system (Applied Biosystems, Foster City, CA, USA). PCR reac-
tions consisted of 2.5 μl of TaqMan® Universal Master Mix II, no UNG,
0.25 μl of TaqMan® Gene EXpression Assay, 1.75 μl of UltraPure™
distilled water, and 0.5 μM cDNA. PCR cycling was as follows: 10 min
at 95 °C, followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min.
Samples were run in triplicate. β-Actin was used as the endogenous
reference transcript. The results of the PCR reactions were analyzed by
ABI PRISM SDS 2.1 software.Results
HCD induces obesity and hyperleptinemia, but limited insulin resistance in
PS19 mice; EX reduces hyperleptinemia without reducing body weight
PS19mice fed HCD showed a signiﬁcant increase in the bodyweight
from 4 months to the experimental endpoint (10 months), and around
20% body weight gain was observed after 5 months compared with
mice fed SD. HCD + EX PS19 mice did not show any signiﬁcant reduc-
tion in body weight compared with the HCD PS19mice, and the change
in body weight with age was almost identical in these two groups
(Fig. 1A). This indicated that metabolic and pathological changes in
the EX groupwere not due to a reduction in the fat volume. The average
fasting serum insulin levels in theHCDgroup seemed elevated, butwere
not statistically signiﬁcant (Fig. 1B), and there was no signiﬁcant differ-
ence in the levels of fasting blood glucose (Fig. 1C). The IGTT showed a
mild elevation in blood glucose at 15, 60, and 120min, and representative
areas under the curve (AUC) were higher in HCD than in SD. HCD + EX
showed a slight elevation in blood glucose only at 120min, but no differ-
ence in AUC (Fig. 1C), whereas in the ITT there was no difference in the
peak rate of lowering blood glucose (SD at 30 min, HCD and HCD + EX
at 45 min). Additionally, AUC showed no differences in each group, al-
though the declining rate of lowering blood glucose after insulin injection
was slower inHCD (Fig. 1D).Moreover, western blotting of brain homog-
enate samples for pAKT, a downstream target of insulin signaling,
showed no signiﬁcant difference in each group (Fig. 1D). These data indi-
cated that the glucose metabolic abnormality seemed to be mild, and
there was limited insulin resistance. Meanwhile, the serum leptin level
in HCD was signiﬁcantly elevated. EX normalized the level, indicating
that HCD-induced leptin resistance was recovered in EX (Fig. 1E). In SD,
because of a little dispersion in BW and serum leptin concentrations
(Figs. 1A, E), the correlation between BW and leptin was ambiguous
(y = 0.067x + 0.93, R2 = 0.024, p = 0.94). However, in HCD and
HCD + EX, there were signiﬁcant proportionate correlations (HCD,
y = 1.1x + 22.5, R2 = 0.75, p b 0.01; HCD + EX, y = 0.43x + 10.6,
Fig. 1.High calorie diet (HCD) induces obesity and hyperleptinemia, but not insulin resistance; voluntary exercise (EX) restores those abnormalities. The average bodyweight in PS19mice
fed the HCD is signiﬁcantly increased comparedwith PS19mice fed the standard chow diet (SD). Meanwhile, EX with a runningwheel does not decrease the average bodyweight
(A). Although the average insulin level is higher in HCD, it is not signiﬁcant (B). Intraperitoneal glucose tolerance tests (IGTT) showmild elevated blood glucose levels in HCD-fed
PS19 mice at 15, 60 and 120 min, although the fasting glucose levels in each group are identical (n = 13 (SD), 12 (HCD), 6 (HCD + EX)). Areas under the curve (AUC) of IGTT in
HCD are greater than SD (C) (n = 12 (SD), 10 (HCD), 6 (HCD+ EX)). Meanwhile, insulin tolerance tests demonstrated no difference in AUC and the peak rate of lowering blood
glucose in each group, although slightly higher blood glucose levels at 15 and 30 min are seen in HCD (D). Moreover, western blotting of brain homogenate samples for pAKT, a
downstream target of insulin signaling, showed no signiﬁcant difference in each group (panel D) indicating that the glucose metabolic abnormality seemed to be mild, and there
was limited insulin resistance. Serum leptin is about three times higher in HCD than SD, but EX completely abrogates the change (E). Total cholesterol and triglyceride levels are
slightly elevated in HCD (F, G). n = 13 (SD), 12 (HCD), 10 (HCD + EX) (except IGTT, ITT). *, p b 0.05; **, p b 0.01 to SD; error bars, 1 SE.
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signiﬁcantly higher in HCD than in HCD + EX (p b 0.01), indicating EX
improved leptin sensitivity.
Cholesterol and triglyceride were mildly elevated in HCD, but
returned to normal in EX (Figs. 1F, G). This data on metabolic changes
indicated that HCD induced obesity, hyperleptinemia, and mild glucose
metabolism abnormalities, but limited insulin resistance, and EX
completely reversed the observed hyperleptinemia.HCD enhances tau pathology and tau insolubility, and EX suppresses tau
enhancements
To compare the tau pathology among the groups, brain sections
were immunostainedwith AT8, an antibody speciﬁc for phosphorylated
tau (Figs. 2A–H).WTmice did not show any AT8-positive staining in the
CA1 (Fig. 2D) or CA3 (Fig. 2H) regions. Although the distribution of tau-
positive neurons, which were mainly located in the hippocampus,
Fig. 2.HCD enhances, but EXmitigates tau pathology and synaptic degeneration. Immunohistochemistry of AT8 antibody (A–H), speciﬁc for phosphorylated tau protein, reveals enhanced
tau pathology in HCD PS19 mice (B, F) compared with SD PS19 mice (A, E), and HCD+ EX PS19 mice showmilder tau pathology (C, G) compared with HCD PS19 mice. There is no AT8
staining inWT (D, H). Statistical analysis (n= 4, each group) indicated that in the CA1 region, the number of AT8-positive neurons (black bar)was increased in HCD PS19mice compared
to SD PS19 mice, although the total neuron number was unchanged (M); however, in the CA3 region, the number of AT8-positive neurons (black bar) was mildly increased in HCD PS19
mice. The neuronal loss was signiﬁcant in HCDmice (N). Syntaxin staining in PS19 mice shows synaptic degeneration in the CA3 region (I, compare withWT (L)). HCD reduces syntaxin
staining more (J), whereas syntaxin staining in HCD + EX PS19 mice (K) is similar to the SD PS19 mice (I). Proteins were extracted from mouse brains after mixing with RIPA buffer
(50 mM Tris, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP40, 5 mM EDTA; pH 8.0, and protease inhibitor cocktail) and centrifuging at 50,000 ×g for 40 min at 4 °C in an
ultracentrifuge. The supernatantswere used as RIPA-soluble samples (O, upper panel), and the RIPA-insoluble pelletswere extractedwith 70% formic acid (FA) to recover highly insoluble
protein (O, lower panel; P). Although HCD+ EX shows no change in the expression levels of tau protein in the RIPA-soluble samples (O, upper panel) probedwith a 17026 polyclonal tau
antibody, RIPA-insoluble tau (O, lower panel) is increased in the HCD PS19mouse brains. Slow-migrating bands (O, lower panel, arrow) are clearly seen and are strongly detected by p-tau
speciﬁc antibodies T181 (P, upper panel, arrow) and AT8 (P, lower panel, arrow) in the HCD group, indicating that a highly-phosphorylated form of the insoluble-tau protein is markedly
increased in the HCD PS19 mouse brains. Scale bars, 50 μm. *, p b 0.05, to SD; error bars, 1 SE; n = 4/group.
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PS19mice showedmuch stronger tau pathology in the CA1 (Fig. 2B) and
CA3 (Fig. 2F) regions compared with the SD PS19 mice (Figs. 2A, E). TheHCD + EX PS19 mice exhibited a milder tau pathology than did the
HCD PS19 mice (Figs. 2C, G). Statistical analysis (n = 4, each group)
also demonstrated enhanced tau pathology in CA1 and CA3, and mild
Fig. 3. HCD activates tau kinases, but EX attenuates the activation. To assess the kinase ac-
tivities involved in tau phosphorylation, western blot analysis was performed for active
and inactive kinases, including GSK3β, CDK5 and MAPKs (p38, JNK, ERK), in PS19 brain
samples from WT and from SD, HCD and HCD + EX mice. For all enzymes except
GSK3β, the phosphorylated (p-) form is the activated form; p-GSK3 is the inactivated
form. HCD clearly enhanced the activation of p38, and CDK5, but not JNK, ERK or GSK3β.
EX suppresses p38, CDK5, and JNK.
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generation is one of the earliest pathological changes in PS19 mice
(Yoshiyama et al., 2007), we compared synaptic loss in the CA3 region
using immunohistochemistry for syntaxin, which stains presynaptic
terminals (Figs. 2I–L). Syntaxin staining was intense in the synapse-rich
granular layer of CA3 in 10-month-old non-transgenic wild type (WT)
mice (Fig. 2L), but was decreased in SD PS19 (Fig. 2I) and HCD + EX
PS19 mice (Fig. 2K). Staining was almost completely abolished in HCD
PS19mice (Fig. 2J). This indicated thatHCDaccelerated synaptic degener-
ation, and the addition of EX suppressed it.
Because more tau-positive neurons were observed in HCD, the
brain tissue from mice was subsequently analyzed for RIPA-soluble
and RIPA-insoluble tau. The expression levels of RIPA-soluble tau were
almost identical in each group (Fig. 2O, upper panel). However, RIPA-
insoluble tau was increased in HCD (Fig. 2O, lower panel). In particular,
a slowlymigrating band (Fig. 2O, lower panel, arrow),whichwas highly
phosphorylated and speciﬁcally recognized by AT8 (Fig. 2P, lower
panel), was intense in HCD PS19 mouse brain samples in the RIPA-
insoluble fraction. Western blotting with another phosphorylated tau-
speciﬁc antibody, T181, demonstrated that tau in the RIPA-insoluble
fractions was also hyperphosphorylated in HCD PS19 mice (Fig. 2P,
upper panel). Interestingly, T181 recognized lower molecular bands
strongly, suggesting that the RIPA-insoluble fraction might contain
T181-positive truncated or degraded tau proteins.
HCD activates p38 and CDK5, but EX suppresses JNK, p38, and CDK5
Immunohistochemical and biochemical studies indicated that EX
attenuated the insolubility and hyperphosphorylation of tau caused by
HCD. To elucidate biological alternations in tau, we examined several
putative tau kinases and other related kinases (Fig. 3). Speciﬁcally, the
activated and inactivated forms of GSK-3β, CDK5, and MAPKs were an-
alyzed. Activity of these enzymes is controlled by phosphorylation state,
and although most of these enzymes are activated by phosphorylation,
GSK3β is inactivated by phosphorylation. In WT mice and in SD, HCD,
and HCD + EX PS19 mice, expression of enzymes was similar in all
groups, which suggested that basic expression levels of these enzymes
were not affected by the transgene, HCD, or EX. HCD showed enhanced
enzyme activity for p38 and CDK5, and EX suppressed this effect. JNK
activity was clearly suppressed by EX, although it was not clear if HCD
enhanced JNK activity. Interestingly, EX did not suppress JNK activity
in SD-fed PS19 mice (Supplemental Fig. 1F). In addition to phosphory-
lating tau, JNK regulates awide spectrumof intracellular signaling path-
ways (Chen, 2012), and is involved in metabolic regulation (Hirosumi
et al., 2002). Suppression of JNK activation by EX might be related to
the corrective effect of EX on the deregulation of metabolism caused
by obesity.
HCD enhances glial activation, but EX suppresses this effect
Microglial-mediated neuroinﬂammation plays an important role in
neurodegeneration in a number of diseases, including tauopathies
(Akiyama et al., 2000). In fact, PS19 mice show microglial activation
preceding tau pathology and neuronal loss (Yoshiyama et al., 2007).
Many studies have indicated that obesity is linked to a state of chronic,
low-grade inﬂammation (Hotamisligil and Erbay, 2008; McArdle et al.,
2013; van Greevenbroek et al., 2013), and exercise is known to produce
anti-inﬂammatory effects (Petersen and Pedersen, 2005; Gleeson et al.,
2011). Thus, we estimatedmicroglial activation by using twomicroglia-
speciﬁc antibodies, Iba1 (Figs. 4A–L) and CD68 (Figs. 4M–O). Immuno-
histochemistry for Iba1 in hippocampal regions CA1 (Figs. 4A, D, G, J),
CA3 (Figs. 4C, F, I, L), and CA4 (Figs. 4B, E, H, K) demonstrated pro-
nouncedmicroglial activation in HCD PS19mice (Figs. 4D–F) compared
to SD PS19 mice (Figs. 4A–C) and WT mice (Figs. 4J–L). Meanwhile, EX
suppressed HCD-related microglial activation (Figs. 4G–I). Higher mag-
niﬁcation images revealed enlarged, strongly Iba1-positive microgliawith thick processes in HCD PS19 mice (Figs. 4D–E, insets), whereas a
few small, faintly Iba1-positive microglia with thin processes were ob-
served in the WT mice (Figs. 4J–L, insets). Microglial activation was
mainly observed in the hippocampus, amygdala, entorhinal cortex,
and brain stem, and corresponded predominantly to regions where
tau pathology was observed (data not shown). Because CD68-positive
microglia mainly appeared in the granular neuronal layer of the hippo-
campus that exhibited neuronal loss in older PS19 mice (Yoshiyama
et al., 2012), we stained hippocampal sections for CD68. More CD68-
positive microglia were seen in the CA3 region of HCD mice (Fig. 4N)
compared with those of SD mice (Fig. 4M) or HCD + EX mice (Fig. 4O).
Astrocytes are also involved in the neuroinﬂammatory process in the
brain (Li et al., 2011), and their activation is closely related to the area of
neurodegeneration (Fukutani et al., 2000). Astrogliosis was observed in
the area exhibiting tau pathology in the PS19 mouse brain (Yoshiyama
et al., 2007), and the distribution of astrogliosis closely paralleled that
Fig. 4.HCD inducesmicroglial activation, but EX suppresses it. Hippocampal sections (CA1 region, A,D,G, J; CA4 region, B, E,H, K; CA3 region, C, F, I, L,M–O) fromSD(A–C,M),HCD(D–F, N) and
HCD+EXPS19mice (G–I, O), and SDWTmice (J–L)were stainedwithmicroglia-speciﬁc antibodies Iba1 (A–L) andCD68 (M–O).HCDenhancesmicroglial activation,whereas EX reduces that
microglial activation. Higher magniﬁcation images (insets) indicate morphological changes: enlarged cytoplasm with shorter thick processes. Scale bars, 50 μm; 10 μm in insets.
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was enhanced in the hippocampal region in HCD mice (Fig. 6D), but
was suppressed in HCD + EX mice (Fig. 6G). The quantitative analysis
of the number of glialﬁbrillary acidic protein (GFAP)-positive astrocytes
in the CA3 (Fig. 6J) and dentate gyrus (Fig. 6K) hippocampal regions in-
dicated that HCD inducedmore astrogliosis, and that EX attenuated this
effect (Figs. 6J, K).Fig. 5. Leptin receptor a (LepRa) highly expresses in active astrocytes and corresponds to the
antibody, which highly recognizes the leptin receptor a (LepRa) and not LepRb, demonstrate
HCD+ EX (C). Similarly, the entorhinal cortex (D) and the amygdala (E), where tau accumula
logical characteristics of theM18 staining in the entorhinal cortex at highermagniﬁcation indica
cortex stainedwithM18,which indicates that expression of LepRa is restricted in the hippocamp
(G, upper area). K20 antibody, which recognizes all isoforms,weakly stains all brain regions bey
the thalamus). A highmagniﬁcation image of the visual cortex shows that K20 stains both neur
stains glial cells and neurons (J-L), but the staining intensities in CA3 regions from SD (J), HCD (K
neurons and glial cells throughout all brain regions, although neurons in the basomedial hypot
weak neuronal nuclear staining in pyramidal neurons in CA3 regions in SD (M), HCD (N) and H
HCD+ EX (R). The staining intensity ofHCD isweaker than SDorHCD+ EX.Westernblot for A
HCD+ EX shows upregulations of both AMPK expression and activity (S). 3V, 3rd ventricle. ScA short isoform of leptin receptor, LepRa, is strongly expressed in activated
astrocytes
In this study, HCD-induced obesity induced hyperleptinemia that was
attenuated by EX without a reduction in body weight. We hypothesized
that hyperleptinemia might play an important role in enhancing tau
pathology and glial activation. This prompted us to investigate thetau pathology distribution. Low magniﬁcation images of brain tissue stained with M18
clear enhanced staining in the hippocampus from HCD (B), compared with SD (A) and
tion is preferentially seen in PS19 mice, are well stained with M18 antibody. The morpho-
te that astrocytes highly express LepRa (F). The boundary area of the hippocampal CA1 and
al area (G, lower area), but is extended neither to the adjacentwhitematter nor the cortex
ond the hippocampus (H) (the upper side is the hilus of hippocampus and the down side is
ons (asterisks) and glial cells (arrowheads) (I). LepRb speciﬁc antibody, CH14014, weakly
) and HCD+ EX (L) are almost identical. This indicates that LepRbmayweakly express on
halamus express most highly (data not shown). Immunohistochemistry for pSTAT shows
CD+ EX (O). The similar tendencywas also seen in hypothalamus in SD (P), HCD (Q) and
MPKand its activated formpAMPK shows suppressed activity of AMPK inHCD.Meanwhile,
ale bars, 100 μm in A–E; 10 μm in F, I–L; 50 μm in G, H, J–H, M–O.
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188 S. Koga et al. / Neurobiology of Disease 71 (2014) 180–192expression of leptin receptors (LepRs) in the brain. LepRs are produced in
several alternatively spliced forms that can be classiﬁed into three groups:
long isoforms (LepRb), short isoforms (LepRa, c, d and f), and secreted iso-
forms (LepRe) (Lee et al., 1996;Wang et al., 1996). LepRb is the only full-
length isoform, and was initially considered to be the functional receptor
based on theﬁnding that it has an extended intracellular domain contain-
ing various motifs required to interact with other proteins and subse-
quently activate signaling pathways (Tartaglia et al., 1995). Most of the
effects of leptin on appetite and body weight are attributable to the cen-
tral nervous system, especially the basomedial hypothalamus, where
LepRb is highly expressed in neurons (Elmquist et al., 1998a, 1998b,
1999). We used three antibodies to distinguish LepR isoforms: M18,
K20, and CH14014. M18 recognizes a portion of the LepR membrane
that is juxtapositional to the cytoplasmic domain, andhas the highest sen-
sitivity for LepRa. It recognizes the other LepRs, but has less sensitivity for
LepRc and LepRd, and the lowest sensitivity for LepRb (Hsuchou et al.,
2009). K20 recognizes all isoforms except LepRe, and CH14014 is a
LepRb-speciﬁc antibody. Low magniﬁcation images of brain tissue from
PS19 mice fed HCD and stained with M18 antibody showed enhanced
staining in the hippocampus (Fig. 5B) compared with PS19 mice fed SD
(Fig. 5A) or HCD+EX (Fig. 5C). Highermagniﬁcation of the hippocampal
CA1 area demonstrated selective staining with M18, which was not ex-
tended to the adjacent white matter or the cortices (Fig. 5G). Additional-
ly, the entorhinal cortex (Fig. 5D) and the amygdala (Fig. 5E), where tau
accumulation is commonly seen in PS19 mice, were highly stained with
M18 antibody. The morphological characteristics of the M18 staining in
the entorhinal cortex at higher magniﬁcation indicated that the LepR ex-
pression was in astrocytes (Fig. 5F). To investigate the LepR isoforms
expressed in these astrocytes, RT-PCR on mRNA samples from primary
cultured astrocytes derived from cortices, including the hippocampus
was performed (Fig. 7A). Homogenate samples from the diencephalon
(DC) showed clear bands of LepRa and b, and weak bands of LepRc, d,
and e. Meanwhile, the primary cultured astrocytes showed clear bands
of LepRa, a weaker band of LepRb, a faint band of LepRc, and trace
bands of LepRd and e. Thus, the primary cultured astrocytes expressed
mainly LepRa, while DC homogenate, which contained neurons, glial
cells other than astrocytes, vessels, andotherparenchyma, predominantly
expressed LepRa and b. These ﬁndings corresponded to the immunohis-
tochemical analysis for LepRs (Fig. 5). K20weakly stained all brain regions
beyond the hippocampus (Fig. 5H). A high magniﬁcation image of the
visual cortex shows that K20 stained both neurons and glial cells
(Fig. 5I). CH14014 weakly stained both glial cells and neurons (J–L),
and the staining intensities in CA3 regions from SD (J), HCD (K), and
HCD + EX (L) were almost identical. These results indicated that
LepRbwaswidely expressed throughout the brain, including the hippo-
campus, neocortices, and hypothalamus (Mercer et al., 1996; Funahashi
et al., 2003). Taken together, M18-stained astrocytes highly expressed
LepRa, which might play a major role in these cells.
HCD induces leptin resistance both in hippocampal and hypothalamic
neurons, but EX restores it
One of themost important signaling pathwaysmedicated by LepRb is
the signal transducer and activator of transcription-3 (STAT3) signaling
pathway. Phosphorylation of STAT3 (pSTAT3) enables its nuclear trans-
location and promotes transcriptional effects. Thus, we performed im-
munochemistry to ascertain the prevalence of pSTAT3. Although an
antibody speciﬁc to pSTAT3 stainednuclei of neurons in the hypothalam-
ic nucleus (Figs. 5P–R), it also weakly stained hippocampal neurons
(Figs. 5M–O). Meanwhile, there was no obvious glial staining, indicating
that STAT3 and its downstream signalingmight not operate in glial cells.
Interestingly, the nuclei positive for pSTAT3 in the hippocampus region
had similar staining in SD (Fig. 5M) and HCD+ EX (Fig. 5O), but weaker
staining in HCD (Fig. 5N), indicating that leptin resistance in HCD mice
(Figs. 5N, Q) occurred not only in hypothalamic neurons (Figs. 5P–R),
but also in hippocampal neurons (Figs. 5M–O). Because leptin canmodulate AMP-activated protein kinase (AMPK) activity following bind-
ing to LepRb (Kola et al., 2006), we also performed a western blot for
AMPK and its activated form, pAMPK. Although there was considerable
sample-to-sample variation in the amount of pAMPK, it generally
seemed decreased in samples from HCD mice. Interestingly, the AMPK
expression was increased in HCD + EX, suggesting that EX might in-
crease both the activation and expression of AMPK (Fig. 5S).
HCD enhances LepRa expression in astrocytes, but EX suppresses it
Astrocytes were activated and their LepRa expressionwas enhanced
in the hippocampus of HCD PS19 mice. Therefore, we quantiﬁed the
activation of astrocytes and their LepRa expression in double-stained
hippocampal sections using an astrocyte-speciﬁc antibody for GFAP
(Figs. 6A, D, G) and theM18antibody (Figs. 6B, E, H). The staining clearly
demonstrated astrocyte activation by intense GFAP staining, thickened
cellular processes, and evidence of hypertrophy in the hippocampus in
HCD mice (Fig. 6D). M18 staining was also stronger in astrocytes from
HCD mice (Fig. 6E). Additionally, astrocyte proliferation was conﬁrmed
by counting the number of astrocytes (Figs. 6J, K). Merged images
(Figs. 6C, F, I) demonstrated that not all GFAP-positive astrocytes were
stained with M18. Activated astrocytes had increased M18 staining
(Fig. 6F). This indicated that activation of astrocytes might induce and
enhance LepRa expression. Quantitative analysis in hippocampal CA3
(Fig. 6J) and dentate gyrus (Fig. 6K) conﬁrmed enhanced astrogliosis
and LepRa expression in the hippocampus of HCD mice, and EX sup-
pressed those changes (Figs. 6J, K).
Leptin induces Il-1β and TNF-α expression in primary cultured astrocytes
via a LepRb-independent pathway
We speculated that astrocyte activation and enhanced astrocyte
LepRa expression in HCD PS19 mice might play an important role in
the enhanced tau pathology by activating inﬂammation. In addition to
controlling appetite, it has been reported that leptin increases the ex-
pression of pro-inﬂammatory cytokines in some cell types, including
IL-1β and TNF-α (Hosoi et al., 2000; Alefﬁ et al., 2005; Shen et al., 2005;
Hekerman et al., 2007; Wong et al., 2007; Lafrance et al., 2010); it has
also been reported that inﬂammation increases the levels of leptin and
its receptors (Fernandez-Riejos et al., 2010; Gan et al., 2012). Because
the expression of LepRa was enhanced in astrocytes in HCD-induced
obese PS19 mice, we speculated hyperleptinemia induced inﬂammatory
reactions in astrocytes with enhanced LepRa expression. To examine
whether leptin induces pro-inﬂammatory cytokines in astrocytes, we
conducted a leptin-load experiment in PCA. In this experiment, we used
LepRb-deﬁcient mice (db/db) and WT mice. Real time PCR analysis of
TNF-αmRNA levels demonstrated a dose-dependent increase in both
WT and db/dbmice (Fig. 7D) in response to leptin. This clearly indicated
that leptin likely induced TNF-α via LepRa and not via LepRb. Interest-
ingly, IL-1β was increased only in db/db mice but not in WT mice
(Fig. 7B). This suggests that the upregulation of short forms of LepRs
(probably LepRa) induced by LepRb-deﬁciency in db/dbmicemight en-
hance IL-1β expression. Although C-C motif chemokine 2 (CCL2) (also
called monocyte chemotactic protein-1 (MCP-1)), a small cytokine in-
volved in neuroinﬂammatory processes, is highly expressed in astro-
cytes and neurons in the mouse brain (Ransohoff et al., 1993), leptin
failed to alter mRNA levels of CCL2 (Fig. 7C).
Discussion
The most discriminative and important points in this study are that
the HCD-induced obese tauopathy model mice we generated showed
hyperleptinemia, but not obvious insulin resistance, and that EX amelio-
rated the hyperleptinemia without reducing body weight. These model
mice and unique experimental conditions allowed us to explore the rela-
tionship between hyperleptinemia and changes related to enhanced tau
Fig. 6.HCD enhances, but EX attenuates astrogliosis and leptin receptor a (LepRa) expression in astrocytes. The immunostaining for GFAP (A, D, G) clearly demonstrates astroglial activation in
HCD PS19 mice (D) compared with SD (A), and EX attenuates the astroglial activation (G). Immunostaining with M18 antibody (B, E, H), which preferentially recognizes LepRa, shows
colocalization of GFAP and LepRa (C, F, I). The number of astrocytes positive for LepRa is increased in HCD (~50%) (F), but decreased in SD (~10%) (C) and HCD+ EX (~30%) (I). Higher mag-
niﬁcation images (insets) show that enhanced expression of LepRa is seen inmore activated astrocytes. Quantitative analysis of cells positive for GFAP or LepRa indicates that signiﬁcantlymore
GFAP- and LepRa-positive cells are found in the CA3 region (J) and the dentate gyrus (DG) (K) of the hippocampus (n = 4). Scale bars, 20 μm; 10 μm in insets. Error bars, 1 SE.
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ties that limited insulin signaling abnormality or other metabolic factors
might play a role in enhancing tau pathology. TheHCDweusedhere con-
tains relatively lower fat and calories than the HCD used in a majority of
diet-induced obesity studies; HCD usually contains around 35% fat, 60%
cal from fat, and 550 cal/100 g. Meanwhile, HCD in this study contained
15.3% fat, 32% cal from fat and 415 cal/100 g. Therefore, the degree of
obesity in this study was around 20% body weight gain, while that in
other papers is usually more than 50% body weight gain, compared to
the SD-fed mice. Additionally, the exercise quantity in HCD + EX in
PS19 was about 10% less than that in WT mice (data not shown). This
might be one of the reasons why EX did not reduce the body weight in
HCD+EX PS19mice. Recently, Leboucher et al. (2013) also demonstrat-
ed that obesitywithout insulin resistance enhanced hippocampal tau pa-
thology in other tauopathy mouse model (THY-Tau22). This also
indicates that mechanisms other than insulin signaling abnormalities
play an important role in enhanced taupathology inducedbyobesity. Be-
cause no reduction in the body weight was observed in the transgenic
mice, the fat volume of the HCD + EX mice was presumably similar to
that of the HCD PS19 mice. In fact, magnetic resonance spectroscopy
and imaging of the body composition of the mice in vivo demonstratedthat the voluntary exercise with the running wheel rarely changed the
lean mass weight in obese MC4R-knockout mice and WT mice
(Haskell-Luevano et al., 2009). EX activates LepR signaling pathways in
HCD-induced obese mice (Flores et al., 2006; Ropelle et al., 2008), conse-
quently lowering serum leptin levels (Krawczewski Carhuatanta et al.,
2011). Krawczewski Carhuatanta et al. (2011) reported that HCD + EX
mice showed a reduction in body weight with intracerebroventricular
(ICV) leptin injection, but HCD-fed sedentary mice showed no reduction,
even though themice had the same fat mass as the HCD+ EXmice. This
indicated that EX improved HCD-induced leptin resistance independent
of the increased adipose tissue (adiposity). These data support our spec-
ulation that EX might reduce leptin concentration by improving leptin
resistance and not by reducing adipose tissue. Meanwhile, it has been
reported that EX has beneﬁcial effects on neurodegeneration and inﬂam-
mation in both the presence and absence of obesity (Adlard et al., 2005;
Cotman et al., 2007; Bradley et al., 2008; Balducci et al., 2010). We
found no signiﬁcant beneﬁcial effects of EX on tau pathology (Supple-
mental Figs. 1A, B), tau insolubility (Supplemental Fig. 1F), microglial
activation (Supplemental Figs. 1C, D), astrocytic LepRa expression (Sup-
plemental Fig. 1E) or metabolic parameters (Supplemental Table 1) in
SD-fed PS19 mice, although western blotting showed that ERK1/2
Fig. 7. The mRNA levels of leptin receptor isoforms and the effects of leptin on primary
cultured astrocytes (PCA). RT-PCR analysis shows that cortical primary cultured astrocytes
(PCA) from wild type mice predominantly express LepRa (98 bp), slightly express LepRb
(81 bp), and barely express LepRc (88 bp), LepRd (119 bp) or LepRe (117 bp). Meanwhile,
the level of LepRb is comparable to LepRa inmRNA extracted from the diencephalon (DC)
homogenates (A). The same RT-PCR procedurewithout template was done for the control
experiment (C). Real time PCR demonstrates that leptin signiﬁcantly increases the mRNA
expression levels of TNF-α in a dose-dependentmanner in bothwild type (WT) astrocytes
and LepRb-deﬁcient mouse (db/db) astrocytes (D) but not the level of CCL2 (C) (n = 5).
Interestingly, high concentrations of leptin induce IL-1β only in only db/db mouse
astrocytes (B). (A) M: 100 pb ladders; C: No template. (B) *: p b 0.03 to 0 ng/ml.
(D) **: p b 0.01 to 0 ng/ml and 100 ng/ml; p b 0.03 to 10 ng/ml. !!: p b 0.01 to all other
concentrations. ##: p b 0.01 to all other concentrations. Error bars, 1 SE.
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that EX itself had fewer direct effects on tau pathology and glial activa-
tion, therefore, we speculated that the hyperleptinemia induced by
HCD and the suppression of that hyperleptinemia by EX might be the
mainmechanism alternating tau pathology and glial activation, although
we cannot exclude the possibility that other pathomechanisms related to
obesity and EX play a role in the pathological changes. Additionally,
because we did not use cages with the blocked runningwheel as con-
trols, environmental differences including cage circumstances might
have an affect on the pathology andmetabolic changes. Thus, further,
more precise experiments are required to show the roles of persistent
hyperleptinemia in tau pathology and neurodegeneration. Although
the evaluation of HCD effects on cognitive and behavioral functions
must be important as same as pathological changes, we did not analyze
those, because old PS19 mice showed motor symptoms (paralysis). Re-
cently, Knight et al. (2014) reported that high-fat diet inducedmemory
impairment without enhanced amyloid or tau pathology in 3xTgAD
mice (APPSwe, PS1M146, TAUP301L). This indicates that obesity itself
might affect the cognitive functions without enhanced AD pathological
changes.
Leptin is primarily thought to be an anti-obesity hormone because
its main physiological function is to prevent obesity by regulating the
balance between food intake and energy expenditure. This activity
occurs in the basomedial hypothalamus. Although hypothalamic nuclei
express LepRb in the greatest density, other LepRs are abundantly
expressed in neurons and glial cells throughout the brain (Merceret al., 1996; Funahashi et al., 2003), suggesting that leptin might play
some role in physiological or pathological processes in the brain besides
balancing food intake and energy expenditure. In fact, beneﬁcial effects
of leptin on neuronal survival have been reported (Signore et al., 2008;
Folch et al., 2012). Leptinmitigates tauphosphorylation in cultured neu-
ronal cells (Greco et al., 2008), and continuous intraperitoneal injection of
leptin in amyloidogenic transgenic mice (CRND8) reduced amyloid
burden and tau phosphorylation in vivo (Greco et al., 2010). Additionally,
the pro-inﬂammatory effects of leptin have been shown in a variety of
different cell types (Hosoi et al., 2000; Alefﬁ et al., 2005; Shen et al.,
2005; Hekerman et al., 2007; Wong et al., 2007; Lafrance et al., 2010).
Hyperleptinemia induced by peritoneal dialysis with glucose-containing
ﬂuid increased expression of pro-inﬂammatory cytokines including
TNF-α and IL-6 in visceral adipose tissue in mice. Interestingly, these
effects were stronger in obese, LepRb-deﬁcient db/db mice compared
with their non-obese littermates (db/m), characterized by an upregula-
tion of LepRa expression (Leung et al., 2012). Chronic ICV administration
of leptin activated astrocytes and enhanced GFAP and vimentin expres-
sion in adult male rats. Additionally, obese adult male rats with
hyperleptinemia caused by neonatal overnutrition showed similar
changes in glial structural proteins (Garcia-Caceres et al., 2011). In our
study, HCD-induced obesity also caused astrocytic activation with
enhanced GFAP expression. These results indicate that high levels of
circulating leptin induced by obesity might act on astrocytes similarly
to chronic ICV administration of leptin, suggesting that the effects of
leptin on astrocytes might not be suppressed when so-called “leptin re-
sistance” occurs, in which leptin effects on neurons and neuronal circuits
are down-regulated (Fig. 8).
Because there are few studies about LepRa and its functions, the
function of LepRa in astrocytes is not clear, but analysis of astrocytic
LepR knockout mice (ALKO) provides some indications about LepRa
function in astrocytes. Interestingly, ALKO showed less hyperleptinemia
and GFAP expression than WT mice when HCD was supplied, although
the differences between ALKO and WT mice were not seen when SD
was supplied (Jayaram et al., 2013). They speculated that in the case of
prolonged HCD, astrocytic LepRs became highly reactive to circulating
concentrations of leptin, followed by astroglial activation and proinﬂam-
matory cytokine secretion, which eventually led to neuroinﬂammation.
Neuroinﬂammation reduces sensitivity of neurons to leptin (leptin resis-
tance), enhancing hyperleptinemia evenmore (Jayaramet al., 2013). This
speculation is based on a series of pathological events in the hypothala-
mus that explain the impaired leptin signaling. Fig. 8 shows a model of
how hyperleptinemia acts in the hypothalamus and hippocampus in
the obese tau mouse model. Hyperleptinemia caused by HCD-induced
obesity reduces the leptin sensitivity of neurons in the hypothalamus,
further increasing hyperleptinemia while enhancing the sensitivity of
leptin in astrocytes (astrogliosis and enhanced expression of LepRa)
and accelerating inﬂammatory responses, including the secretion of
pro-inﬂammatory cytokines and microglial activation. Thus, the en-
hanced neuroinﬂammation induced by hyperleptinemia could accelerate
tau pathology and neurodegeneration with tau hyperphosphorylation.
Moreover, downregulation of leptin sensitivity in hippocampal neurons
(leptin resistance) simultaneously might reduce the suppressive effects
of tau phosphorylation caused by leptin (Greco et al., 2009) and the neu-
roprotective effects of leptin (Tezapsidis et al., 2009). Our ﬁndings do not
mean that persistent hyperleptinemia directly initiates tau pathology, but
they do indicate that persistent hyperleptinemia could accelerate any
existing tau pathology.
In conclusion,we showed that persistent hyperleptinemia caused by
HCD-induced obesity enhanced astrogliosis, increased astrocytic LepRa
expression, and increased tau pathology in a tauopathy mouse model.
These pathological deteriorationswere restored by EX,which improved
leptin sensitivity. The effects of obesity on tau pathology are not easy to
deﬁne because they include the effects of obesity itself and the effects of
diseases caused by obesity. Although it is inappropriate to simplistically
apply the results in this study to humans, hyperleptinemia might be
Fig. 8. Schematic representation of effects of HCD-induced hyperleptinemia on glial activation, tau pathology and neurodegeneration in PS19 mice. HCD induces obesity and the down-
regulation of leptin sensitivity (leptin resistance), leading to hyperleptinemia. Astrocyte activation and LepRa expression in the hypothalamus caused by chronic hyperleptinemia further
reduces leptin sensitivity. Simultaneously, hyperleptinemia accelerates neuroinﬂammation, including astroglial activation andmicroglial activation, and pro-inﬂammatory cytokine secre-
tion in the hippocampus and related brain areas where tau pathology and neurodegeneration commonly appear. Additionally, the downregulation of leptin sensitivity decreases neuro-
protective effects of leptin. Meanwhile, EX improves the leptin sensitivity.
191S. Koga et al. / Neurobiology of Disease 71 (2014) 180–192a key pathomechanism that links the effects of obesity and exercise
with AD.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.nbd.2014.08.015.
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